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In conditions requiring repeated blood transfusion or where iron metabolism is abnormal,
heart failure may result from accumulation of iron in the heart (cardiac siderosis). Death due
to heart failure from cardiac iron overload has accounted for considerable early mortality
in β-thalassemia major. The ability to detect iron loading in the heart by cardiovascular
magnetic resonance using T2* sequences has created an opportunity to intervene in the
natural history of such conditions. However, effective and well tolerated therapy is required
to remove iron from the heart. There are currently three approved commercially available
iron chelators: deferoxamine, deferiprone and deferasirox. We review the high quality
randomized controlled trials in this area for iron chelation therapy in the management of
cardiac siderosis.
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INTRODUCTION
In conditions of iron overload, either due to recurrent blood trans-
fusion or abnormal iron metabolism, iron accumulation within
organs can have fatal consequences. Beta-thalassemia major (TM)
is a condition of abnormal hemoglobin resulting in profound ane-
mia that requires lifelong regular blood transfusion, typically from
the age of 2 years. As a consequence of the repeated transfusions
and the body’s inability to clear excess iron, iron can build up
within tissues. The accumulation of iron within the heart (car-
diac siderosis) can result in heart failure and this has been the
commonest cause of death in TM. The development of iron chela-
tors offered a solution to this problem, but long-term experience
showed persistently high and premature cardiac mortality. This
has been related in large part to conventional measures of iron
loading such as serum ferritin and liver iron concentration being
poor surrogates of iron loading in the heart. It is possible to have
high levels of iron loading in the liver without signiﬁcant cardiac
loading and vice versa. Consequently cardiac siderosis may not
be identiﬁed until late, when it presents with heart failure that is
associated with a very poor prognosis.
Over recent decades, the observation that iron reduces mag-
netic resonance (MR) signal has lead to the development of
targeted MR sequences to assess the tissue iron concentrations
in the liver and the heart. The use of cardiovascular magnetic
resonance (CMR) to quantify the parameter T2∗ as a measure of
myocardial iron concentration has been particularly important as
it remains the only technique available for this purpose (Anderson
et al., 2001; Baksi and Pennell, 2014). T2∗ assessment has nowbeen
robustly validated,(Kirk et al., 2009; Carpenter et al., 2011) is well
established and is widely used (Carpenter et al., 2013). In addition
to being able to identify iron loading in the heart and liver, the T2∗
technique can be used to assess the efﬁcacy of iron chelators and to
guide therapy. Prior to the development of CMR T2∗, establishing
the efﬁcacy of iron chelation therapies onmyocardial siderosis was
not possible with any accuracy in the absence of cardiac biopsy.
Little data was available to accurately guide the application of
iron chelators or assess their safety and patient compliance with
treatment.
There are few randomized control trials (RCT) of iron chelation
for cardiac siderosis. In addition to the paucity of data, the robust-
ness of the presented data is variable. We describe and review
the published trials, relating them to the recent guidelines for
the management of β-thalassemia major by the American Heart
Association (AHA; Pennell et al., 2013). The efﬁcacy of the iron
chelators for liver iron is not discussed in this review, and we focus
on heart failure due to cardiac siderosis as the main driver of mor-
tality.We only discuss RCTs using T2∗ MRas an endpoint, because
it remains the only validated technique to measure myocardial
iron. Myocardial T2∗ is considered “normal” when >20 ms. Car-
diac iron loading is considered “present” with T2∗ <20 ms, and is
considered severe with T2∗ <10 ms because the rate of heart fail-
ure increases dramatically below this threshold (Anderson et al.,
2001).
COMMERCIALLY AVAILABLE IRON CHELATORS
Currently, there are three commercially available products with
FDA and EU approval for iron chelation in the clinical setting. As
well as varying in themode of administration, there are signiﬁcant
differences between the three chelators with regard to efﬁcacy,
tolerability, and patient compliance.
DEFEROXAMINE
The ﬁrst iron chelator approved for clinical use was deferoxam-
ine. The greatest drawback with this agent is that due to poor gut
uptake, it needs to be given parenterally (either subcutaneously,
or in heart failure due to iron overload by intravenous infusion).
The short half life results in typical administration for 8–12 h
per day for at least 5 days of the week. This has a profound
impact on patient compliance and considerable work has been
done to provide devices for subcutaneous drug delivery. Once
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severe cardiac iron loading is present, months to years of careful
therapy is needed to clear the iron. Even when used as a contin-
uous intravenous infusion, deferoxamine only clears myocardial
iron at 5% per month (Pennell et al., 2006; Tanner et al., 2007).
Side effects of therapy include deafness, visual disturbance and
growth retardation as well as a high frequency of skin reactions.
DEFERIPRONE
Deferiprone was licensed around 30 years later than deferoxam-
ine. Deferiprone is rapidly absorbed from the gastrointestinal
tract and is therefore taken orally, usually three times a day.
The oral formulation has signiﬁcant compliance advantages over
deferoxamine. Signiﬁcant side effects include agranulocytosis, gas-
trointestinal disturbance and arthropathy. Given the risk of neu-
tropenia, weekly monitoring of the neutrophil count is advised.
Deferiprone is commonly used in combinationwith deferoxamine
for enhanced iron clearance.
DEFERASIROX
The most recent of the chelators is deferasirox. This is taken orally
with rapid absorption and can be taken once daily. Adverse events
are typically gastro-intestinal upset, rash and raised creatinine.
More serious adverse events include Fanconi syndrome, and eye
and ear toxicity. Monitoring of renal and hepatic function are
recommended for deferasirox.
RANDOMIZED CONTROLLED TRIAL DATA COMPARING IRON
CHELATORS IN THE HEART
There have been three RCTs examining the role of the iron chela-
tors in cardiac siderosis using T2∗ CMR as an endpoint. The ﬁrst
RCT compared oral deferiprone monotherapy against subcuta-
neous deferoxamine (Pennell et al., 2013). The achieved dose of
deferiprone was 92mg/kg per day and deferoxamine was 43mg/kg
for 5.7 days perweek. The improvement inmyocardial T2∗ was sig-
niﬁcantly greater for deferiprone thandeferoxamine (27%vs. 13%;
P = 0.023). Left ventricular (LV) ejection fraction (EF) increased
signiﬁcantly more in the deferiprone treated group (3.1% vs. 0.3%
absolute units; P = 0.003). This RCT established that deferiprone
was superior to deferoxamine over 1 year for the removal of
cardiac iron, and the improvement of LV EF in patients with
asymptomatic myocardial siderosis. A further report from this
trial also showed that right ventricular EF also improved more in
the deferiprone patients, than with deferoxamine (Alpendurada
et al., 2010).
The second RCT compared combination treatment of
deferiprone plus deferoxamine against deferoxamine alone in 65
patients withmyocardial T2∗ from 8 to 20ms representing a range
from severe to mild cardiac siderosis (Pennell et al., 2006). There
were signiﬁcant improvements in the combined treatment group
compared with deferoxamine alone in myocardial T2∗ (ratio of
change in geometric means +50% versus +24%; P = 0.02).
The combined group also showed signiﬁcantly great improve-
ment in absolute LV EF (2.6% versus 0.6%; P = 0.05), and
absolute endothelial function (8.8% versus 3.3%; P = 0.02). A
further report from this trial showed that right ventricular EF also
improved more in the combined group, than with deferoxamine
alone (Alpendurada et al., 2012).
The third RCT (CORDELIA trial) compared oral deferasirox
against subcutaneous deferoxamine (Pennell et al., 2014). This
was a prospective, randomized comparison of deferasirox (target
dose 40 mg/kg per day) vs. subcutaneous deferoxamine (50–
60 mg/kg per day for 5–7 days/week) for myocardial iron removal
in 197 thalassemia major patients with myocardial siderosis (T2∗
6–20 ms) and no signs of cardiac dysfunction. The geometric
mean of the myocardial T2∗ improved with deferasirox from
11.2 ms to 12.6 ms at 1 year (+12%) and with deferoxam-
ine from 11.6 ms to 12.3 ms (+7%). The between-arm ratio
of the geometric means was 1.056 with the 95% conﬁdence
intervals of 0.998 and 1.133). The lower boundary was greater
than the pre-speciﬁed margin of 0.9, establishing non-inferiority
of deferasirox vs. deferoxamine (P = 0.057 for superiority
of deferasirox). Mean LVEF remained stable and within the
normal range after 1 year of treatment with deferasirox (66.9–
66.3%) and deferoxamine (66.4–66.4%). The change in mean
LVEF after 1 year was not different between the two treatments
(P = 0.54).
There are two meta-analyses of trials reporting cardiac iron,
but they both have signiﬁcant limitations in including trials using
non-T2∗ assessment technology and also non-randomized trials
(Mamtani and Kulkarni, 2008; Xia et al., 2013). This demonstrates
the paucity of data in the literature and emphasises the need to
focus on the three gold standard randomized controlled trials
described above.
OTHER DATA AND GUIDELINES FOR USE
DEFERIPRONE VERSUS DEFEROXAMINE
The superiority of deferiprone monotherapy over standard defer-
oxamine therapy has been suggested by retrospective and cross-
sectional studies (Anderson et al., 2002; Pepe et al., 2006, 2011).
RCT data indicate that deferiprone is the most efﬁcacious of
these agents for reducing myocardial iron, clearing cardiac iron
at nearly double the rate of deferoxamine, and also improving EF,
an effect not observed with deferoxamine (Pennell et al., 2013).
This remains the only prospective randomized control trial of
deferipronemonotherapy compared to deferoxamine, and further
data would be welcome, as recommended by a Cochrane review
(Fisher et al., 2013). The AHA guidelines on heart management
in thalassaemia major, indicate that deferiprone monotherapy is
useful in patients with cardiac siderosis, and it is also suitable
for patients with reduced LVEF or asymptomatic LV dysfunction
(Carpenter et al., 2013).
COMBINED DEFERIPRONE AND DEFEROXAMINE VERSUS
DEFEROXAMINE MONOTHERAPY
The RCT by Tanner showed that combined treatment with
deferiprone and deferoxaminewas superior to deferoxamine alone
in removing cardiac iron and improving EF. These ﬁndings accord
with other trial data (Daar and Pathare, 2006; Kattamis et al., 2006;
Kolnagou and Kontoghiorghes, 2006; Christoforidis et al., 2007)
and a Cochrane review which again suggested that further trial
data would be helpful (Fisher et al., 2013). The AHA Guidelines
indicate that combined treatment is commonly used where car-
diac iron loading is moderate to severe or when LV function is
impaired (Carpenter et al., 2013).
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MONOTHERAPY WITH DEFERASIROX
The efﬁcacy of deferasirox monotherapy with regard to its ability
to reduce myocardial iron has now been established in a prospec-
tive randomized control trial of good size (Alpendurada et al.,
2012). Non-inferiority to deferoxamine was demonstrated. Also
of note was LV function remained stable during treatment with
both deferasirox and deferoxamine, and consequently, the AHA
guidelines does not recommend the use of deferasirox as ﬁrst line
treatment where there is established depression of LV EF, or in
those with severe iron loading (Carpenter et al., 2013). Data inves-
tigating the impact of combination therapy with deferasirox and
deferiprone would be direct comparison of interest, as would a
trial of deferasirox against deferiprone.
ACUTE HEART FAILURE DUE TO IRON OVERLOAD
Continuous intravenous deferoxamine is the default consensus
treatment for acute heart failure due to myocardial iron toxic-
ity. At present, there is very limited RCT data in this setting. A
small trial of iron chelation in heart failure found both deferoxam-
ine monotherapy and combination therapy with deferiprone and
deferoxamine to be effective in improving LVEF and myocardial
T2∗ (Porter et al., 2013). A non-randomized trial found combined
treatment to be effective in severe cardiac siderosis with reduced
LV EF (Tanner et al., 2008).
CONCLUSION
The assessment of myocardial iron by T2∗ CMR is now established
as fundamental to the best practice management of thalas-
saemia. This has enabled the investigation of which chelation
treatment regime is suitable for myocardial iron loading. Unfor-
tunately, many published studies have suboptimal design and
are essentially observational with low patient numbers, and do
not contribute signiﬁcantly to the evidence base for determining
cardiac treatment. T2∗ CMR is pivotal to inform management
and prolong survival. This is reﬂected no more strongly than
in that data showed a 71% reduction in mortality in the UK β-
thalassemia major population consequent on the introduction of
routine screening for cardiac siderosis by CMR T2∗(Modell et al.,
2008).
Whilst all the available iron chelation therapies appear to be
effective if given in high enough doses with patient compliance,
from the available evidence, deferiprone appears to have superior
efﬁcacy compared to deferoxamine, and the effect of deferox-
amine is superior when combined with deferiprone compared
to deferoxamine alone. Additionally, deferasirox appears to have
equivalent efﬁcacy to deferoxamine. Each of these therapies has
advantages and disadvantages and tailoring therapy to individual
patients is important to optimize outcome. Despite the current
evidence base, further larger, well-designed, randomized con-
trolled trials are desirable, and greater data on compliance is
needed. Well targeted application of these therapies in combi-
nation with T2∗ CMR will improve the prognosis of thalassaemia
major patients.
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